BAY 1193397 / Bayer - LARVOL DELTA

Pharmacokinetics, Safety, and Tolerability of the α -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects. (PubMed, Clin Pharmacol Drug Dev) - "At supratherapeutic plasma concentrations, there were slight transient increases in norepinephrine levels, heart rate, and blood pressure that were more pronounced after a single dose compared to steady state and appeared to be maximum concentration dependent. The results of the presented studies support the conduct of subsequent clinical trials with BAY 1193397 in patients with diabetes and compromised microcirculation."

Clinical • Journal • PK/PD data • Diabetes • Metabolic Disorders

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure (clinicaltrials.gov) - P2; N=23; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed

Trial completion

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure (clinicaltrials.gov) - P2; N=22; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure (clinicaltrials.gov) - P2; N=18; Recruiting; Sponsor: Bayer; Trial completion date: Jun 2019 ➔ Oct 2019; Trial primary completion date: May 2019 ➔ Aug 2019

Clinical • Trial completion date • Trial primary completion date